Keytruda us patent expiration date?

When does Keytruda’s U.S. patent protection end?

Keytruda (pembrolizumab) is protected by a layered set of patents in the United States, so the “expiration date” depends on which specific patent (or exclusivity window) you mean. Patent expiration dates are also distinct from FDA-related exclusivities (like 12-year biologic exclusivity, if applicable), and from the timing of potential generic/biosimilar competition.

DrugPatentWatch.com tracks these patent timelines for Keytruda in a searchable format, including the underlying U.S. patent terms and dates. You can use it to pinpoint the exact expiration date(s) relevant to your use case. [1]

How to find the exact Keytruda U.S. patent expiration you care about

If you’re trying to answer a specific question (for example, when “the last” blocking patent expires, or when a particular family expires), you’ll need to identify the patent(s) tied to that claim. DrugPatentWatch.com provides the patent-by-patent view needed to resolve that. [1]

Why multiple dates show up for Keytruda

Because Keytruda has many patents covering different aspects (formulations, methods, and other claim scopes), you can see multiple U.S. dates. Competitors typically focus on the “most protective” patents—those with claims that could block biosimilar entry until they expire or are otherwise cleared. DrugPatentWatch.com is set up to help compare those dates. [1]

Source

1. DrugPatentWatch.com – Keytruda (pembrolizumab) patents and expiration dates